Advertisement
U.S. markets closed
  • S&P 500

    4,604.37
    +18.78 (+0.41%)
     
  • Dow 30

    36,247.87
    +130.49 (+0.36%)
     
  • Nasdaq

    14,403.97
    +63.98 (+0.45%)
     
  • Russell 2000

    1,880.82
    +12.57 (+0.67%)
     
  • Crude Oil

    71.26
    +1.92 (+2.77%)
     
  • Gold

    2,020.80
    -25.60 (-1.25%)
     
  • Silver

    23.29
    -0.77 (-3.20%)
     
  • EUR/USD

    1.0764
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2450
    +0.1160 (+2.81%)
     
  • GBP/USD

    1.2551
    -0.0043 (-0.34%)
     
  • USD/JPY

    144.8930
    +0.7020 (+0.49%)
     
  • Bitcoin USD

    43,911.36
    +29.32 (+0.07%)
     
  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     
  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     
  • Nikkei 225

    32,307.86
    -550.45 (-1.68%)
     

Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross

Galectin Therapeutics Inc. (GALT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, GALT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."

A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.

A successful golden cross event has three stages. It first begins when a stock's price on the decline bottoms out. Then, its shorter moving average crosses above its longer moving average, triggering a positive trend reversal. The third and final phase occurs when the stock maintains its upward momentum.

This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.

Shares of GALT have been moving higher over the past four weeks, up 15.4%. Plus, the company is currently a #2 (Buy) on the Zacks Rank, suggesting that GALT could be poised for a breakout.

Once investors consider GALT's positive earnings outlook for the current quarter, the bullish case only solidifies. No earnings estimate has gone lower in the past two months compared to 1 revisions higher, and the Zacks Consensus Estimate has increased as well.

With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on GALT for more gains in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Galectin Therapeutics Inc. (GALT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement